UTRECHT, the Netherlands, July 8, 2010 /PRNewswire/ -- InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of its Scientific Advisory Board (SAB). The SAB will further guide the Company in the development of cancer therapies based on the unique functions of its proprietary miRNAs.

The SAB is chaired by Emile E. Voest, MD, PhD, Professor of Medical Oncology at the Department of Medical Oncology, UMC Utrecht, the Netherlands.

Other distinguished members are:

- Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department. of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; - William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute and Senior Associate Member at the Broad Institute of Harvard and MIT, Boston, USA; - Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; - Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen, Belgium; - Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and Professor of Genome Biology at Utrecht University, Professor of Human Genetics and head of the Research section of the Department of Medical Genetics, UMC Utrecht and staff scientist at Hubrecht Institute, Utrecht, the Netherlands; - Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies and staff scientist at Hubrecht Institute, the Netherlands.

We are very pleased with the formation of our SAB and feel honored to collaborate with this experienced team that is highly committed advising the Company on moving forward its research and development towards the clinic, said Roel Schaapveld, CEO of InteRNA Technologies. The complementary knowledge of the renowned clinicians and scientists in this team will play a significant role in our RD programs and success of the Company.

Edwin Cuppen, scientific co-founder of InteRNA Technologies, commented: While fundamental research has now unequivocally demonstrated the importance of miRNA's in regulation and deregulation of biological processes, InteRNA Technologies has in the past few years build up a unique position in converting this knowledge into miRNA-based cancer treatment strategies. These activities are now further supported by a wealth of knowledge and expertise through this SAB, which will undoubtedly further accelerate the path towards miRNA-based drugs.

About InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.

InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research.

See for more information http://www.interna-technologies.com.

SOURCE: InteRNA Technologies B.V.

CONTACT: Contacts: Roel Schaapveld, PhD, MBA, CEO, InteRNA TechnologiesB.V., Phone: +31(0)302532386, E-mail: schaapveld@interna-technologies.com .